Cognitive Changes With Gabapentin Treatment

The Washington University

Status: Terminated

Conditions: Neuralgia Peripheral; Pain

Treatments: Diagnostic Test: BTACT; Diagnostic Test: BPI; Diagnostic Test: NPSI; Diagnostic Test: HADS; Diagnostic Test: SLP9; Drug: Gabapentin

Study type: Observational

Funder types: Other

Identifiers

NCT04106011

201908050

Details and patient eligibility

About

This is a single-cohort, prospective, observational study evaluating the effects of gabapentin on cognition. The goal of the study is to determine whether there is a measurable change in cognitive function from baseline in patients who are prescribed gabapentin for the treatment of neuropathic pain.

Enrollment: 3 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age between 18 and 85
2. Diagnosis of neuropathic pain
3. Patient report of average daily pain intensity in the last week >3 on 0-10 Numerical Rating Scale (NRS).
4. Able and willing to sign an IRB-approved written informed consent

Exclusion criteria

1. Current pregabalin treatment
2. Patient has started taking a new pain medication, or has changed their pain medication dose, in the past 4 weeks.
3. Treatment with opioids exceeding 60mg MME.
4. Severe cognitive impairment that is documented in medical chart.

Trial design

3 participants in 1 patient group

Patients with Neuropathic Pain

Treatment:

Diagnostic Test: BTACT

Diagnostic Test: NPSI

Diagnostic Test: HADS

Diagnostic Test: SLP9

Diagnostic Test: BPI

Drug: Gabapentin